George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
|Articles|September 16, 2008
- April30 2003
- Volume 10
- Issue 8
FEE-BASED FINANCES
Author(s)Michael Sheehan
Advertisement
Investment News
Result:
Brokers who get their incomefrom commissions on transactionsthey execute are losing ground to fee-basedbrokers who charge based onthe time spent on a client's account,or on the amount of assets in theclient's portfolio, according to arecent report in . Theconflict of interest that is inherent inthe commission-based broker's relationshipwith the client got tarredwith the same brush that paintedWall Street's analysts as too cozy withthe stocks they analyzed. Thenumber of fee-based brokers is onthe rise, with some big-name firmslike Merrill Lynch setting up programsto dispense fee-based financialplanning advice.
Articles in this issue
about 18 years ago
Portfolio CHECK-UPabout 18 years ago
Don't Delay, Start Saving for Retirementabout 18 years ago
Gain Perspective on Variable Annuitiesabout 18 years ago
Docs Miss the $ Boat-Againabout 18 years ago
Establish E-communication with Patientsabout 18 years ago
Enjoy E-mail Paydays for Consultationsabout 18 years ago
Confront HIPAA as a Former Soviet Wouldabout 18 years ago
Take Steps to Avoid IRS' Audit Dragnetabout 18 years ago
Take Fiscal Advice from a Fellow Doctorabout 18 years ago
Doc's Stocks Current StandingsAdvertisement
Related to this article
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
2
FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B
3
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5